Livestream to Spotlight Aditxt’s Autoimmune Innovation and its Vision to Address One of the Fastest Growing Global Health Challenges

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced a live discussion focused on its wholly owned subsidiary Adimune™, Inc. (“Adimune™”), which is advancing therapeutics designed to address autoimmune diseases.

The livestream, hosted by Jack Marks of Wall Street Reporter, will take place on July 22, 2025, at 1:00 p.m. ET and will feature Amro Albanna, Co-founder and CEO of Aditxt. The session will provide an in-depth look at Adimune™’s pioneering approach, potential upcoming milestones, and the broader market opportunity in autoimmune disease conditions that affect millions of people worldwide and continue to rise.

Event Details:

What: Live Discussion – “Adimune™: Modulating the Immune System”

Who: Amro Albanna, CEO of Aditxt

Host: Jack Marks, Wall Street Reporter

When: July 22, 2025, at 1:00 p.m. ET

Where: Streaming live: Click Here

Key Topics Will Include:

• The science behind immune modulation and how Adimune aims to restore immune tolerance
• Initial target indications including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome
• Adimune’s planned first-in-human clinical trials
• The potential of Adimune™’s platform to transform treatment paradigms across multiple autoimmune conditions
• How Adimune™ fits into Aditxt’s broader Acquire, Build, Capitalize (ABC) strategy

“We believe that autoimmunity is one of the fastest growing and least understood global health crises. At Adimune™, we’re not aiming to just treat symptoms—we’re working to retrain the immune system to prevent the disease altogether,” said Amro Albanna, CEO of Aditxt. “This discussion will give the audience a deeper look into how we’re seeking to advance toward clinical trials and why we believe Adimune™ could be one of the most important biotech platforms for addressing autoimmunity.”

About Wall Street Reporter NEXT SUPER STOCK livestream

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEOs of promising, publicly traded companies, and market experts. www.WallStreetReporter.com

About Next Super Stock conference

Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join the next livestream event:

https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

About Adimune™

Adimune™ is a pre-clinical stage biopharmaceutical company pioneering a new class of immune modulation therapies designed to restore natural immune tolerance. Adimune™’s mission is to advance immune health by providing targeted, long-term solutions that minimize reliance on chronic immunosuppression—transforming treatment for autoimmune diseases and organ transplantation.

One of Adimune™’s innovations is ADI-100™, a first-in-class Apoptotic DNA Immunotherapy™ that mimics the body’s natural mechanisms for maintaining immune tolerance. This proprietary platform uses nucleic acid technology to deliver two coordinated signals: one encoding BAX, a protein that promotes targeted apoptosis, and another encoding a modified disease-specific antigen to re-establish immune tolerance.

To learn more and view the corporate presentation, please visit adimune.com.

About Aditxt, Inc.

Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health, and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women’s health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem’s shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to Adimune’s ability to commence in-human clinical trials on the proposed timeline, if at all; the ability of ADI-100 to induce tolerance as designed with respect to the currently contemplated indications; expected growth of Adimune; the size and expected growth of markets which Adimune is targeting; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt’s ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt’s ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company’s SEC filings, including Aditxt’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.

For more information, please visit www.aditxt.com.

Follow Aditxt on:

LinkedIn: https://www.linkedin.com/company/aditxt

Facebook: https://www.facebook.com/aditxtplatform/

View source version on businesswire.com: https://www.businesswire.com/news/home/20250626978888/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20250722372414/en/